Eyonis Inc., a Median Technologies company focused on applying artificial intelligence to the early detection and diagnosis of cancer, today announced that Median Technologies has entered into a strategic commercial agreement with Olea Medical, a Canon Medical Systems company, that will expand U.S. access to eyonis® LCS Lung Cancer Screening. The broader agreement also covers Europe and other markets that may be mutually agreed upon over time.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Intelligenome and Cornell University entered into a research and development subaward agreement to support the development of a rapid, low-cost, and portable diagnostic solution for tuberculosis (TB), according to the company. The project is part of a National Institutes of Health (NIH) funded program focused on improving access to technologies for human healthcare.

Alveo Technologies, Inc. (Alveo), a leader in portable molecular sensing solutions, today announced a strategic partnership with The University of Texas Medical Branch (UTMB) to develop point-of-care diagnostics for viral hemorrhagic fevers across West Africa. The point-of-care diagnostic will provide real-time pathogen detection at clinical sites in Nigeria and Sierra Leone, supporting UTMB's Lassa fever research program—a major international initiative.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

NanoSomiX, Inc., a biotechnology company focused on blood‑based analytics using extracellular vesicles (EVs), including brain‑derived EVs, today announced plans to collaborate with Beckman Coulter Diagnostics, a global leader in clinical diagnostics, to explore the development of next‑generation immunoassays for neurodegenerative diseases.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Today, Biocartis, an innovative molecular diagnostics company, and Discovery Life Sciences (“Discovery”), a global leader in biomarker specialty laboratory services and biospecimen solutions, are pleased to announce a strategic collaboration to deliver seamless, end-to-end precision oncology solutions to pharmaceutical and biotech customers worldwide.